| Identification | Back Directory | [Name]
Nilotinib hydrochloride anhydrous | [CAS]
923288-95-3 | [Synonyms]
Nilotinib hydrochloride Nilotinib hydrochloride anhydrous 4-Methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(3-pyridinyl)-2-pyrimidinyl]amino}benzamide hydrochloride (1:1) | [Molecular Formula]
C28H23ClF3N7O | [MDL Number]
MFCD16038432 | [MOL File]
923288-95-3.mol | [Molecular Weight]
565.99 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 100 mg/mL (176.68 mM);Ethanol: 2 mg/mL (3.53 mM) | [Water Solubility ]
Water: Insoluble | [InChIKey]
VTGGYCCJUPYZSX-UHFFFAOYSA-N | [SMILES]
C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)(=O)C1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1.Cl |
| Hazard Information | Back Directory | [Uses]
Nilotinib Hydrochloride might be useful in treatment of chronic myelogenous leukemia. It is a COVID19-related research product. | [in vivo]
Nilotinib hydrochloride (oral gavage, 40 mg/kg, daily, 4 weeks) shows equivalent or higher antitumor effects in BALB/cSLc-nu/nu mice with GIST xenograft[2].
Nilotinib hydrochloride has a significant healing effect on the macroscopic and microscopic pathologic scores and ensures considerable mucosal healing in the indomethacin-induced enterocolitis rat model while decreases the PDGFR α and β levels and apoptotic scores in the colon[3].
| Animal Model: | BALB/cSLc-nu/nu mice with GIST xenograft (GK1X, GK2X and GK3X)[2] | | Dosage: | 40 mg/kg | | Administration: | Oral gavage; daily; 4 weeks | | Result: | Inhibited tumor growth by 69.6% in GK1X, 85.3% in GK2X and 47.5% in GK3X xenograft line. |
|
|
|